Search - tctmd.com

Displaying 501 - 520 of 1865

Sort: Relevancy | Date

Validated ARC-HBR Criteria Highlight ‘Eye-opening’ Proportion of PCI Patients at Risk

News Daily News

Validated ARC-HBR Criteria Highlight ‘Eye-opening’ Proportion of PCI Patients at Risk

Yael L. Maxwell

March 03, 2020

Antiplatelets Add Risk in Newly Diagnosed A-fib Patients: GARFIELD-AF

News Daily News

Antiplatelets Add Risk in Newly Diagnosed A-fib Patients: GARFIELD-AF

March 02, 2020

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

News Daily News

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

February 28, 2020

News Daily News

Bioprosthetic Valve Thrombosis Rare but Not Benign: New Insights

Yael L. Maxwell

February 28, 2020

Less Leaflet Thrombosis in Low-Risk TAVR Patients Treated With Oral Anticoagulation

News Conference News CRT 2020

Less Leaflet Thrombosis in Low-Risk TAVR Patients Treated With Oral Anticoagulation

Michael O'Riordan

February 26, 2020

PCI-Related MIs Not Linked to Mortality at 1 Year: Onyx ONE

News Conference News CRT 2020

PCI-Related MIs Not Linked to Mortality at 1 Year: Onyx ONE

Michael O'Riordan

February 25, 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

February 25, 2020

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

News Conference News CRT 2020

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

February 24, 2020

News Daily News

Early CVD Readmissions and Mortality Patterns Differ in Canada and the US

Yael L. Maxwell

February 18, 2020

Clinical Crossroads On Optimal Antithrombotic Therapy In Patients Treated With Pci Intravenous Antiplatelet Therapy In High Risk Acs

Presentation JIM 2020

Clinical Crossroads On Optimal Antithrombotic Therapy In Patients Treated With Pci Intravenous Antiplatelet Therapy In High Risk Acs

Presenter: Dominick Angiolillo

February 13, 2020

Intravenous antiplatelet therapy in high risk ACS:GPIIb/IIIa inhibitors are still a good option

Presentation JIM 2020

Intravenous antiplatelet therapy in high risk ACS:GPIIb/IIIa inhibitors are still a good option

Presenter: Marco Ferlini

February 13, 2020

Cirrhosis Tied to Poor Outcomes in the Months After PCI

News Daily News

Cirrhosis Tied to Poor Outcomes in the Months After PCI

February 12, 2020

Outcome Differences Between Men and Women With PAD: EUCLID Insights

News Daily News

Outcome Differences Between Men and Women With PAD: EUCLID Insights

February 11, 2020

ACS After TAVR a Unique Condition With Poor Prognosis

News Daily News

ACS After TAVR a Unique Condition With Poor Prognosis

February 05, 2020

SYNTAX Score Predicts Long-term Benefits of Left Main PCI and CABG: MAIN-COMPARE

News Daily News

SYNTAX Score Predicts Long-term Benefits of Left Main PCI and CABG: MAIN-COMPARE

Michael O'Riordan

February 03, 2020

Dual Antiplatelet therapy: How Long to Continue after PC

Presentation BIT 2020

Dual Antiplatelet therapy: How Long to Continue after PC

Presenter: Baren Chakraborty

February 02, 2020

News Daily News

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

January 20, 2020

Embolization Coils May Be an Option for Leaks After LAA Occlusion

News Daily News

Embolization Coils May Be an Option for Leaks After LAA Occlusion

January 15, 2020

News Daily News

No Fewer MACE With Ticagrelor vs Clopidogrel in ACS Patients After PCI: Registry

January 15, 2020

The Cancer Patient Needing PCI Poses Conundrums for Care

News Features

The Cancer Patient Needing PCI Poses Conundrums for Care

January 14, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.